Nektar Therapeutics
(NASDAQ : NKTR)

( )
NKTR PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
Loading NKTR News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.00%167.451.2%$752.43m
INCYIncyte Corporation
0.00%141.281.7%$625.70m
GILDGilead Sciences, Inc.
0.00%67.831.0%$594.24m
CELGCelgene Corporation
0.00%123.371.0%$512.15m
BIIBBiogen Inc.
0.00%277.871.3%$452.42m
REGNRegeneron Pharmaceuticals, Inc.
0.00%369.142.1%$317.75m
KITEKite Pharma, Inc.
0.00%76.3818.8%$210.13m
ALXNAlexion Pharmaceuticals, Inc.
0.00%120.081.6%$205.79m
TSROTESARO, Inc.
0.00%155.7816.1%$177.45m
ESPREsperion Therapeutics, Inc.
0.87%39.3518.7%$165.93m
ILMNIllumina, Inc.
0.00%167.793.7%$165.24m
AUPHAurinia Pharmaceuticals Inc.
0.00%8.536.3%$148.77m
CLVSClovis Oncology, Inc.
0.00%67.1817.5%$141.46m
VRTXVertex Pharmaceuticals Incorporated
0.00%90.042.2%$134.96m
EXELExelixis, Inc.
0.00%20.487.0%$106.18m

Company Profile

Nektar Therapeutics is a clinical-stage biopharmaceutical company, which engages in developing drug candidates that utilize its PEGylation and polymer conjugate technology platforms. Its products includes of drug candidates of therapeutic areas, including oncology, pain, anti-infectives, anti-viral, and immunology. It provides small molecule drugs, peptides and other potential biologic drug candidates. It's drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. The company was founded in 1990 and is headquartered in San Francisco, CA.